Strata Critical Medical, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Tables)

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Jun. 30, 2021

Summary of Significant Accounting Policies

Schedule of Anti-dilutive securities excluded from the potential shares of common stock


		For the Three and Nine Months Ended June 30,
		2021		2020
Warrants to purchase shares of Class A Common Stock		14,166,667		—
Options to purchase shares of Class A Common Stock		9,689,826		8,486,974
Restricted shares of Class A Common Stock		703,137		—
Total potentially dilutive securities		24,559,630		8,486,974

Disaggregation of revenue


		For the Three Months Ended
		June 30,
Product Line		2021			2020
Short distance		$	5,721		$	629
MediMobility organ transport and jet			6,500			2,636
Other			730			173
Total Revenue		$	12,951		$	3,438


		For the Nine Months Ended
		June 30,
Product Line		2021			2020
Short distance		$	8,900		$	5,767
MediMobility organ transport and jet			19,753			9,089
Other			1,557			259
Total Revenue		$	30,210		$	15,115